The disease impacts industrialized countries most strongly, but changes in lifestyle, including in developing countries, have led to a dramatic increase in obesity worldwide, a significant risk factor for developing Type 2 diabetes.
The worldwide pharmaceutical market for Type 2 diabetes, 60% of which is represented by oral antidiabetics, is expected to nearly double from $26 billion in 2011 to $48.8 billion in 2021.